Soriano D, Dulitzki M, Schiff E, Barkai G, Mashiach S, Seidman D S
Department of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Israel.
Br J Obstet Gynaecol. 1996 Nov;103(11):1068-73. doi: 10.1111/j.1471-0528.1996.tb09584.x.
To determine the safety and efficacy of intramuscular oxytocin plus ergometrine compared to intravenous oxytocin for prevention of postpartum haemorrhage, and the significance of administration at the end of the second stage of labour compared with that after the third stage.
A prospective cohort study.
A university affiliated tertiary medical centre.
Two thousand one hundred and eighty-nine women delivering singletons during 40 consecutive weeks.
Postpartum haemorrhage (> 500 ml), prolonged third stage (> 30 min), retained placenta (> 60 min), elevated blood pressure (systolic > 150 mmHg, diastolic > 100 mmHg).
The rate of postpartum haemorrhage was not significantly different for oxytocin-ergometrine compared with oxytocin, when administered at the end of the second stage of labour (odds ratio 1.10, 95% confidence interval (CI) 0.75-1.61) or after the third stage (odds ratio 0.95, 95% CI 0.68-1.34). The patients receiving oxytocics at the end of the second stage of labour had significantly lower rates of postpartum haemorrhage, for both oxytocin-ergometrine (odds ratio 0.69, 95% CI 0.49-0.98) and oxytocin (odds ratio 0.60, 95% CI 0.41-0.87), compared with those treated after the third stage.
Administration of oxytocin alone is as effective as the use of oxytocin plus ergometrine in the prevention of postpartum haemorrhage, but associated with a significantly lower rate of unpleasant maternal side effects. Oxytocics administered after delivery of the fetal head compared with after the placental expulsion are associated with a significantly lower rate of postpartum haemorrhage.
确定肌肉注射缩宫素加麦角新碱与静脉注射缩宫素预防产后出血的安全性和有效性,以及第二产程结束时给药与第三产程后给药相比的意义。
前瞻性队列研究。
一所大学附属的三级医疗中心。
连续40周内分娩单胎的2189名妇女。
产后出血(>500ml)、第三产程延长(>30分钟)、胎盘滞留(>60分钟)、血压升高(收缩压>150mmHg,舒张压>100mmHg)。
在第二产程结束时给药(优势比1.10,95%置信区间(CI)0.75 - 1.61)或第三产程后给药(优势比0.95,95%CI 0.68 - 1.34)时,缩宫素 - 麦角新碱组与缩宫素组的产后出血率无显著差异。与第三产程后接受缩宫素治疗的患者相比,第二产程结束时接受缩宫素治疗的患者产后出血率显著更低,缩宫素 - 麦角新碱组(优势比0.69,95%CI 0.49 - 0.98)和缩宫素组(优势比0.60,95%CI 0.41 - 0.87)均如此。
单独使用缩宫素在预防产后出血方面与使用缩宫素加麦角新碱同样有效,但产妇不良副作用发生率显著更低。与胎盘娩出后给药相比,胎头娩出后给药的缩宫素与显著更低的产后出血率相关。